INHIBRX BIOSCIENCES, INC. Research and Development Expense
INHIBRX BIOSCIENCES, INC. (INBX) reported Research and Development Expense of $23.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. research and development expense for the quarter ending 2026-06-30 was $23.90M, a 7.33% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. research and development expense for the quarter ending 2026-03-31 was $25.22M, a 31.62% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. research and development expense for the quarter ending 2025-12-31 was $25.35M, a 24.03% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. research and development expense for the quarter ending 2025-09-30 was $28.54M, a 26.63% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. research and development expense for fiscal 2025 was $113.03M, a 44.52% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. research and development expense for fiscal 2024 was $203.74M, a 6.32% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. research and development expense for fiscal 2023 was $191.64M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.90M 10-Q · filed 2026-08-13 | $49.12M 10-Q · filed 2026-08-13 | $74.47M derived: sum of 3 quarters · filed 2026-08-13 | $103.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $25.22M 10-Q · filed 2026-05-14 | $50.57M derived: sum of 2 quarters · filed 2026-05-14 | $79.10M derived: sum of 3 quarters · filed 2026-05-14 | $101.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $25.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $53.88M derived: sum of 2 quarters · filed 2026-03-19 | $76.15M derived: sum of 3 quarters · filed 2026-08-13 | $113.03M 10-K · filed 2026-03-19 |
| 2025-09-30 | $28.54M 10-Q · filed 2025-11-14 | $50.80M derived: sum of 2 quarters · filed 2026-08-13 | $87.68M 10-Q · filed 2025-11-14 | $121.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $22.27M 10-Q · filed 2026-08-13 | $59.14M 10-Q · filed 2026-08-13 | $92.51M derived: sum of 3 quarters · filed 2026-08-13 | $131.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $36.88M 10-Q · filed 2026-05-14 | $70.24M derived: sum of 2 quarters · filed 2026-05-14 | $109.14M derived: sum of 3 quarters · filed 2026-05-14 | $176.77M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $33.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $72.26M derived: sum of 2 quarters · filed 2026-03-19 | $139.89M derived: sum of 3 quarters · filed 2026-03-19 | $203.74M 10-K · filed 2026-03-19 |
| 2024-09-30 | $38.89M 10-Q · filed 2025-11-14 | $106.53M derived: sum of 2 quarters · filed 2025-11-14 | $170.38M 10-Q · filed 2025-11-14 | $252.47M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $67.63M 10-Q · filed 2025-08-13 | $131.48M 10-Q · filed 2025-08-13 | $213.57M derived: sum of 3 quarters · filed 2025-08-13 | $251.63M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $63.85M 10-Q · filed 2025-05-14 | $145.94M derived: sum of 2 quarters · filed 2025-05-14 | $184.00M derived: sum of 3 quarters · filed 2025-05-14 | $218.10M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $82.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $120.15M derived: sum of 2 quarters · filed 2025-03-17 | $154.25M derived: sum of 3 quarters · filed 2025-03-17 | $191.64M 10-K · filed 2025-03-17 |
| 2023-09-30 | $38.06M 10-Q · filed 2024-11-14 | $72.16M derived: sum of 2 quarters · filed 2024-11-14 | $109.55M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $34.11M 10-Q · filed 2024-08-13 | $71.49M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |